Filing Flows › PTC Therapeutics (PTCT) › Q2 2026
PTC Therapeutics (PTCT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 30, 2026
PTC Therapeutics (PTCT) reported revenue of $361M for the second quarter 2026 (Q2 2026), +102% from a year earlier and +32% from the quarter before. Operating margin was 41.3%, net earnings $83.5M (23.2% of revenue).
PTC Therapeutics, Q2 2026: revenue $361M (+102% year over year), operating margin 41.3%, net earnings $83.5M, operating cash flow $129M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $361M | +32% | +102% |
| Operating profit | $149M | +231% | — |
| Net earnings | $83.5M | — | — |
| Operating cash flow | $129M | — | — |
| Free cash flow | $127M | — | — |
What changed
Revenue was $360.5M in Q2 2026, up 102% year over year and up 32% from the previous quarter. Sephience was the largest line at 42% of revenue. Collaboration and license revenue added $47.7M year over year (up 1620%), 26% of the total change. Emflaza declined 32%.
Operating profit was $149.0M, a 41.3% margin (up 60.9 points year over year). Total costs fell 1% while revenue rose 102%. The fastest-growing cost line was Other operating costs (+104%). Net earnings were $83.5M. The effective tax rate was 14.4%.
Operating cash flow was $129.1M, 155% of net earnings. Non-cash charges added back $15.9M of depreciation and amortization and $23.3M of share-based compensation. Capital expenditures of $2.2M left free cash flow of $126.9M.
Questions
What was PTC Therapeutics' revenue in the second quarter 2026?
PTC Therapeutics (PTCT) reported revenue of $361M for the second quarter 2026 (Q2 2026), +102% from a year earlier and +32% from the quarter before.
Was PTC Therapeutics profitable in the second quarter 2026?
Operating profit was $149M (41.3% of revenue) and net earnings $83.5M.
Source: PTC Therapeutics 10-Q on SEC EDGAR.